EHL Awarded for Revamp of Its Flagship Bachelor
26.11.2019 17:11:00 EET | Business Wire | Press release
EHL has been awarded the World Hospitality Awards (WHA) prize for “Innovation in Education”, in recognition of its revamped Bachelor of Science in International Hospitality Management which leverages the full power of the multi-campus education group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005522/en/
(Graphic: EHL)
First international campus
Establishing an international presence was a paramount factor in EHL’s plans to enrich its students’ learning and broaden their perspectives. With such clear intent to expand into emerging hospitality markets, EHL Group has been authorized to deliver its Bachelor of Science in International Hospitality Management in Singapore. EHL Campus (Singapore)1 will receive its first cohort in the fall of 2021. In the meantime, the Group plans to deliver short courses on site as early as summer 2020.
“We very much look forward to expanding our connection to the local community and participate in this thriving environment. It is with enthusiasm and conviction that we embark on this new adventure. Our commitment to the local economy will start on-campus and extend throughout the country, as we hope to strengthen our existing ties to the Singaporean hospitality industry”, said EHL Group CEO Michel Rochat.
Candidates can visit: https://singapore.ehl.edu and apply to start their Preparatory Year at EHL Campus Lausanne in September 2020 and then begin their Bachelor course as the first cohort at EHL Campus (Singapore) in September 2021.
1 Bachelor, 2 Pathways, 3 Campuses
The novel organization of EHL’s offering, which the WHA has awarded, is best represented by the new slogan 1 Bachelor, 2 pathways, 3 campuses. 1 degree, representing the world-renowned Bachelor degree which is the foundation of EHL’s global recognition, 2 pathways, as EHL Passugg students who are studying to get a professional diploma are now given the opportunity to extend their studies and work towards a university-level degree. Finally, 3 campuses thanks to the third South-East Asian campus in Singapore, in addition to the Swiss campuses in Lausanne and Passugg.
“EHL has become a truly global education provider and now sets itself further apart by enabling students to aspire for bigger, better things either in Switzerland or abroad. We are proud of being recognized for our pioneering efforts and very much look forward to the new global alliances and partnerships that will stem from our Asian foothold”, concluded Michel Rochat.
1EHL Campus (Singapore) is registered as a private education institution in Singapore under the Private Education Act, Enhanced Registration Framework (ERF), Registration No 201731189N, and has received EduTrust Certification Scheme (Certification number EDU-2-2124, valid from June 14 2019 to June 13 2023).
About EHL Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005522/en/
Contact information
EHL Group
Sherif Mamdouh | External Communications Manager
communication@ehl.ch | +41 21 785 10 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom